The Commonwealth of Massachusetts
Executive Office of Health and Human Services
One Ashburton Place, 11th Floor
Boston, MA 02108

DEVAL L. PATRICK
Governor

TIMOTHY P. MURRAY
Lieutenant Governor

JUDYANN BIGBY, M.D.
Secretary

Administrative Bulletin 13-03

114.3 CMR 20.00: Coding Updates for Clinical Laboratory Services

Effective January 1, 2013

Under the authority of regulation 114.3 CMR 20.01(3), "Coding Updates and Corrections," the Executive Office of Health and Human Services (EOHHS) is adding new procedure codes and deleting outdated codes as specified in the calendar year 2013 Centers for Medicare & Medicaid Services New Clinical Laboratory Fee Schedule Test Codes and Final Payment Determinations. The rates for code additions are priced at 74.67% of the prevailing Medicare fee if available, with the exception of code 81217 which directly replaces deleted code S3820. The rate for code 81217 is paid at the current rate of the deleted code S3820 contained in 114.3 CMR 20.00: Clinical Laboratory Services. The changes below are effective January 1, 2013.

All other codes in this bulletin that require pricing are reimbursed at individual consideration (I.C.). Rates listed in this informational bulletin are applicable until revised rates are issued by EOHHS. Deleted codes will no longer be available for use after 2012.

Code	Change	Rate	Code Description
81201	Addition	I.C.	APC (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; full gene sequence
81202	Addition	I.C.	APC (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; known familial variants
81203	Addition	I.C.	APC (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; duplication/deletion variants
81217	Addition	$385.00	BRCA2 (breast cancer 2) (e.g. hereditary breast and ovarian cancer) gene analysis; full sequence analysis; known familial variant
81235	Addition	I.C.	EGFR (epidermal growth factor receptor) (eg, non-small cell lung cancer) gene analysis, common variants (e.g., exon 19 LREA deletion, L858R, T790M, G719A, G719S, L861Q)
81252	Addition	I.C.	GJB2 (gap junction protein, beta 2, 26kDa, connexin 30) (e.g., nonsyndromic hearing loss) gene analysis; full gene analysis
81253	Addition	I.C.	GJB2 (gap junction protein, beta 2, 26kDa, connexin 30) (e.g., nonsyndromic hearing loss) gene analysis; known familial variants
81254	Addition	I.C.	GJB6 (gap junction protein, beta 6, 30kDa, connexin 30)

			(e.g, nonsyndromic hearing loss), gene analysis, common variants (eg, 309kb [del(GJB6-D13S1830)] and 232kb [del(GJB6-D13S1854)])
81321	Addition	I.C.	PTEN (phosphatase and tensin homolog) (e.g., Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; full sequence analysis
81322	Addition	I.C.	PTEN (phosphatase and tensin homolog) (e.g., Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; known familial variant
81323	Addition	I.C.	PTEN (phosphatase and tensin homolog) (e.g., Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; duplication/ deletion analysis
81324	Addition	I.C.	PMP22 (peripheral myelin protein 22) (e.g., Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; duplication/deletion analysis
81325	Addition	I.C.	PMP22 (peripheral myelin protein 22) (e.g., Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; full sequence analysis
81326	Addition	I.C.	PMP22 (peripheral myelin protein 22) (e.g., Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; known familial variant
81479	Addition	I.C.	Unlisted molecular pathology procedure
81500	Addition	I.C.	Oncology (ovarian), biochemical assays of two proteins (CA-125 and HE4), utilizing serum, with menopausal status, algorithm reported as risk score
81503	Addition	I.C.	Oncology (ovarian), biochemical assays of five proteins (CA-125, apoliproprotein A1, beta-2 microglobulin, transferring, pre-albumin), utilizing serum, algorithm reported as a risk score
81506	Addition	I.C.	Endocrinology (type 2 diabetes), biochemical assays of seven analytes (glucose, HbA1c, insulin, hs-CRP, adoponectin, ferritin, interleukin 2-receptor alpha), utilizing serum or plasma, algorithm reporting a risk score
81508	Addition	I.C.	Fetal congenital abnormalities, biochemical assays of two proteins (PAPP-A, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score
81509	Addition	I.C.	Fetal congenital abnormalities, biochemical assays of three proteins (PAPP-A, hCG [any form], DIA), utilizing maternal serum, algorithm reported as a risk score
81510	Addition	I.C.	Fetal congenital abnormalities, biochemical assays of three analytes (AFP, uE3, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score
81511	Addition	I.C.	Fetal congenital abnormalities, biochemical assays of four analytes (AFP, uE3, hCG [any form], DIA), utilizing maternal serum, algorithm reported as a risk score (may include additional results from previous biochemical testing)
81512	Addition	I.C.	Fetal congenital abnormalities, biochemical assays of five analytes (AFP, uE3, hCG [any form], hyperglycosylated hCG, DIA), utilizing maternal serum, algorithm reported as a risk score
81599	Addition	I.C.	Unlisted multianalyte assay with algorithmic analysis
82777	Addition	$13.29	Galectin-3
83890	Deletion	- -	Molecular diagnostics; molecular isolation or extraction, each nucleic acid type (i.e., DNA or RNA)
83891	Deletion	- -	Molecular diagnostics; isolation or extraction of highly purified nucleic acid, each nucleic acid type (i.e., DNA or

			RNA)
83892	Deletion	- -	Molecular diagnostics; enzymatic digestion, each enzyme treatment
83893	Deletion	- -	Molecular diagnostics; dot/slot blot production, each nucleic acid preparation
83894	Deletion	- -	Molecular diagnostics; separation by gel electrophoresis (e.g., agarose, polyacrylamide), each nucleic acid preparation
83896	Deletion	- -	Molecular diagnostics; nucleic acid probe, each
83897	Deletion	- -	Molecular diagnostics; nucleic acid transfer (e.g., Southern, Northern), each nucleic acid preparation
83898	Deletion	- -	Molecular diagnostics; amplification, target, each nucleic acid sequence
83900	Deletion	- -	Molecular diagnostics; amplification, target, multiplex, first 2 nucleic acid sequences
83901	Deletion	- -	Molecular diagnostics; amplification, target, multiplex, each additional nucleic acid sequence beyond 2 (List separately in addition to code for primary procedure)
83902	Deletion	- -	Molecular diagnostics; reverse transcription
83903	Deletion	- -	Molecular diagnostics; mutation scanning, by physical properties (e.g., single strand conformational polymorphisms [SSCP] heteroduplex, denaturing gradient gel electrophoresis ([DGGE], RNA'ase A), single segment, each
83904	Deletion	- -	Molecular diagnostics; mutation identification by sequencing, single segment, each segment
83905	Deletion	- -	Molecular diagnostics; mutation identification by allele specific transcription, single segment, each segment
83906	Deletion	- -	Molecular diagnostics; mutation identification by allele specific translation, single segment, each segment
83907	Deletion	- -	Molecular diagnostics; lysis of cells prior to nucleic acid extraction (e.g., stool specimens, paraffin, embedded tissue), each specimen
83908	Deletion	- -	Molecular diagnostics; amplification, signal, each nucleic acid sequence
83909	Deletion	- -	Molecular diagnostics; separation and identification by high resolution technique (e.g., capillary electrophoresis), each nucleic acid preparation
83912	Deletion	- -	Molecular diagnostics; interpretation and report
83913	Deletion	- -	Molecular diagnostics; RNA stabilization
83914	Deletion	- -	Mutation identification by enzymatic ligation or primer extension, single segment, each segment (e.g., oligonucleotide ligation assay [OLA], single base chain extension [SBCE], or allele-specific primer extension
86152	Addition	I.C.	Cell enumeration using immunologic selection and identification in fluid specimen (e.g., circulation tumor cells in blood);
86153	Addition	I.C.	Cell enumeration using immunologic selection and identification in fluid specimen (e.g., circulation tumor cells in blood); physician interpretation and report
86711	Addition	$14.78	Antibody; JC (John Cunningham) virus
86828	Addition	$40.62	Antibody to human leukocyte antigens (HLA), solid phase assays (e.g., microspheres or beads, ELISA, flow cytometry); qualitative assessment of the presence or absence of antibody(ies) to HLA Class I and Class II HLA antigens

86829	Addition	$30.47	Antibody to human leukocyte antigens (HLA), solid phase assays (e.g., microspheres or beads, ELISA, flow cytometry); qualitative assessment of the presence or absence of antibody(ies) to HLA Class I or Class II HLA antigens
86830	Addition	$82.27	Antibody to human leukocyte antigens (HLA), solid phase assays (e.g., microspheres or beads, ELISA, flow cytometry); antibody identification by qualitative panel using complete HLA phenotypes; HLA Class I
86831	Addition	$70.52	Antibody to human leukocyte antigens (HLA), solid phase assays (e.g., microspheres or beads, ELISA, flow cytometry); antibody identification by qualitative panel using complete HLA phenotypes; HLA Class II
86832	Addition	$129.28	Antibody to human leukocyte antigens (HLA), solid phase assays (e.g., microspheres or beads, ELISA, flow cytometry); high definition qualitative panel for identification of antibody specificities (e.g., individual antigen per bead methodology), HLA Class I
86833	Addition	$117.53	Antibody to human leukocyte antigens (HLA), solid phase assays (e.g., microspheres or beads, ELISA, flow cytometry); high definition qualitative panel for identification of antibody specificities (e.g., individual antigen per bead methodology), HLA Class II
86834	Addition	$364.34	Antibody to human leukocyte antigens (HLA), solid phase assays (e.g., microspheres or beads, ELISA, flow cytometry); semi-qualitative panel (e.g., titer), HLA Class I
86835	Addition	$329.09	Antibody to human leukocyte antigens (HLA), solid phase assays (e.g., microspheres or beads, ELISA, flow cytometry); semi-qualitative panel (e.g., titer), HLA Class II
87631	Addition	$77.76	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (e.g., adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), multiplex reverse transcription and amplified probe technique, multiple types and subtypes, 3-5 targets
87632	Addition	$117.90	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (e.g., adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), multiplex reverse transcription and amplified probe technique, multiple types and subtypes, 6-11 targets
87633	Addition	$218.26	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (e.g., adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), multiplex reverse transcription and amplified probe technique, multiple types and subtypes, 12-25 targets
87910	Addition	$84.44	Infectious agent genotype analysis by nucleic acid (DNA or RNA); ctyomegalovirus
87912	Addition	$84.44	Infectious agent genotype analysis by nucleic acid (DNA or RNA); Hepitatis B virus